Bayer AG stock (DE000BAY0017): Latest developments and business overview

Bayer AG recently reported first-quarter 2026 results, highlighting steady performance in its Crop Science segment despite headwinds in Pharmaceuticals. The company posted group revenue of €13.7 billion for the quarter ended March 31, 2026, up 2% on a comparable basis, according to Bayer IR as of May 6, 2026. This performance underscores Bayer's focus on innovation in agriculture and oncology as key growth drivers.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Bayer AG: core business model

Bayer AG operates as a global life sciences company with three main divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on therapeutics in cardiology, oncology, and women's health, generating about 40% of group sales. Crop Science, contributing around 35%, provides seeds, pesticides, and digital farming solutions. This diversified model allows Bayer to leverage synergies across human and plant health, with R&D spend exceeding €5.5 billion annually as reported in its 2025 Annual Report published March 2026, according to Bayer IR as of March 15, 2026.

The company's strategy emphasizes innovation and sustainability, including a goal to reduce greenhouse gas emissions by 30% per ton of product by 2030. Bayer's acquisition of Monsanto in 2018 for $63 billion integrated leading agrotech capabilities, though it introduced litigation risks from Roundup-related lawsuits.

Main revenue and product drivers for Bayer AG

Pharmaceuticals revenue reached €5.6 billion in Q1 2026, driven by oncology drugs like Nubeqa (darolutamide) and Verquvo, with 12% growth in the segment. Crop Science sales hit €5.1 billion, boosted by soybean seeds and herbicides, up 4% year-over-year. Consumer Health contributed €1.2 billion from brands like Claritin and One A Day, stable amid market pressures, per Bayer Q1 2026 report as of May 6, 2026.

Key products include Xarelto (blood thinner, partnered with J&J), Kerendia for kidney disease, and in Crop Science, Roundup and Liberty herbicides alongside biotech traits. Bayer invests heavily in pipeline assets, with 9 blockbusters exceeding €1 billion in peak sales potential.

Industry trends and competitive position

The global pharmaceuticals market is projected to grow at 6% CAGR through 2030, per IQVIA as of January 2026, driven by aging populations and biologics. Bayer competes with Pfizer, Novartis, and Roche in pharma, holding a top-10 position by revenue. In agribusiness, it rivals Corteva and Syngenta, with a 25% share in seeds post-Monsanto.

Sustainability pressures favor Bayer's digital farming tools like the Climate FieldView platform, used by over 150 million acres globally, enhancing precision agriculture.

Why Bayer AG matters for US investors

Bayer generates over 30% of revenue from North America, with significant US exposure via Pharmaceuticals (Xarelto US sales ~€2 billion annually) and Crop Science (leading soybean seed market share). Shares trade as an ADR on OTC (BAYRY), offering US investors easy access to this €30 billion market cap giant. Litigation updates, like the May 2026 settlement progress on Roundup cases, directly impact valuation, making it relevant for portfolios diversified in healthcare and agrotech.

Conclusion

Bayer AG demonstrates operational resilience with Q1 2026 results beating expectations in key segments, while advancing its pipeline and managing legacy liabilities. The stock traded at €28.50 on Xetra on May 13, 2026, reflecting a year-to-date gain of 5%, according to Boerse Frankfurt as of 05/13/2026. Investors monitoring global life sciences will watch upcoming earnings and legal resolutions for further direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.